Physician profile
Weitong Mu
NPI 1194786624
$4,062.84
in general payments reported to CMS, 2019-2025
23 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $251 · 2021: $487 · 2022: $621 · 2023: $682 · 2024: $804 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,843.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $509.12 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $284.47 | 2019-2025 | |
| Gilead Sciences, INC. | $241.50 | 2019-2025 | |
| Janssen Biotech, INC. | $225.70 | 2019-2025 | Tremfya, Stelara, Simponi |
| Medtronic, INC. | $201.72 | 2022-2024 | Interstim, Pillcam, Gi Genius |
| Boston Scientific Corporation | $115.00 | 2024 | Cre Pro |
| Ironwood Pharmaceuticals, INC | $106.79 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.72 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $67.14 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $62.72 | 2021-2023 | Ocaliva |
| Genzyme Corporation | $59.53 | 2023 | |
| Phathom Pharmaceuticals, INC. | $40.74 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $30.10 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $29.11 | 2024 | Bylvay |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.08 | 2019-2022 | |
| Capsovision, INC. | $24.08 | 2024 | Capsocam Plus |
| Celgene Corporation | $22.32 | 2022 | |
| Ardelyx, INC. | $19.65 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $17.10 | 2023 | Clenpiq |
| Shire North American Group INC | $16.89 | 2019 | |
| Redhill Biopharma INC. | $15.61 | 2021 | |
| Braintree Laboratories, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weitong Mu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.